127 related articles for article (PubMed ID: 35598839)
21. Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.
Wang X; Diamond DJ; Forman SJ; Nakamura R
Int J Hematol; 2021 Nov; 114(5):544-553. PubMed ID: 34561840
[TBL] [Abstract][Full Text] [Related]
22. Time to put the CAR-T before the horse.
Jacobson CA; Ritz J
Blood; 2011 Nov; 118(18):4761-2. PubMed ID: 22053170
[No Abstract] [Full Text] [Related]
23. COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells.
Sachinidis A; Garyfallos A
Int J Rheum Dis; 2022 Jan; 25(1):83-85. PubMed ID: 34766739
[No Abstract] [Full Text] [Related]
24. Promises and limitations of nanoparticles in the era of cell therapy: Example with CD19-targeting chimeric antigen receptor (CAR)-modified T cells.
Jakobczyk H; Sciortino F; Chevance S; Gauffre F; Troadec MB
Int J Pharm; 2017 Nov; 532(2):813-824. PubMed ID: 28764981
[TBL] [Abstract][Full Text] [Related]
25. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.
Paszkiewicz PJ; Fräßle SP; Srivastava S; Sommermeyer D; Hudecek M; Drexler I; Sadelain M; Liu L; Jensen MC; Riddell SR; Busch DH
J Clin Invest; 2016 Nov; 126(11):4262-4272. PubMed ID: 27760047
[TBL] [Abstract][Full Text] [Related]
26. COVID-19 vaccination can occasionally trigger autoimmune phenomena, probably via inducing age-associated B cells.
Mahroum N; Shoenfeld Y
Int J Rheum Dis; 2022 Jan; 25(1):5-6. PubMed ID: 34978156
[No Abstract] [Full Text] [Related]
27. A safe and potent anti-CD19 CAR T cell therapy.
Ying Z; Huang XF; Xiang X; Liu Y; Kang X; Song Y; Guo X; Liu H; Ding N; Zhang T; Duan P; Lin Y; Zheng W; Wang X; Lin N; Tu M; Xie Y; Zhang C; Liu W; Deng L; Gao S; Ping L; Wang X; Zhou N; Zhang J; Wang Y; Lin S; Mamuti M; Yu X; Fang L; Wang S; Song H; Wang G; Jones L; Zhu J; Chen SY
Nat Med; 2019 Jun; 25(6):947-953. PubMed ID: 31011207
[TBL] [Abstract][Full Text] [Related]
28. A second CD19 CAR T-cell infusion: yes or no?
Casucci M; Ciceri F
Blood; 2021 Jan; 137(3):284-286. PubMed ID: 33475747
[No Abstract] [Full Text] [Related]
29. [Application of CD19-CAR T Cells in Refractory Relapsed Acute B Lymphocyte Leukemia].
Bao F; Hu K; Wan W; Tian L; Jing HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1604-1609. PubMed ID: 30501691
[TBL] [Abstract][Full Text] [Related]
30. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
31. Q&A: Carl June on CAR T-cell Therapy.
Blood Cancer Discov; 2020 Jul; 1(1):8-9. PubMed ID: 35015690
[No Abstract] [Full Text] [Related]
32. Early data indicate safety of allogeneic CAR T cells.
Sidaway P
Nat Rev Clin Oncol; 2023 Apr; 20(4):209. PubMed ID: 36750648
[No Abstract] [Full Text] [Related]
33. Safer CAR T-Cell Therapy.
Abbasi J
JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
[No Abstract] [Full Text] [Related]
34. CAR T cells - what have we learnt?
Nat Rev Clin Oncol; 2017 Dec; 15(1):1. PubMed ID: 29242589
[No Abstract] [Full Text] [Related]
35. Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.
Ma F; Ho JY; Du H; Xuan F; Wu X; Wang Q; Wang L; Liu Y; Ba M; Wang Y; Luo J; Li J
Hematol Oncol; 2019 Dec; 37(5):601-608. PubMed ID: 31465532
[TBL] [Abstract][Full Text] [Related]
36. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
Li HH; Zhu P; Wu XQ; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
[TBL] [Abstract][Full Text] [Related]
37. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Kochenderfer JN; Rosenberg SA
Nat Rev Clin Oncol; 2013 May; 10(5):267-76. PubMed ID: 23546520
[TBL] [Abstract][Full Text] [Related]
38. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Wang X; Popplewell LL; Wagner JR; Naranjo A; Blanchard MS; Mott MR; Norris AP; Wong CW; Urak RZ; Chang WC; Khaled SK; Siddiqi T; Budde LE; Xu J; Chang B; Gidwaney N; Thomas SH; Cooper LJ; Riddell SR; Brown CE; Jensen MC; Forman SJ
Blood; 2016 Jun; 127(24):2980-90. PubMed ID: 27118452
[TBL] [Abstract][Full Text] [Related]
39. The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors.
Zander R; Cui W
Hum Vaccin Immunother; 2017 Oct; 13(10):2269-2271. PubMed ID: 28708956
[TBL] [Abstract][Full Text] [Related]
40. Equipping CAR-modified T cells with a brake to prevent chronic adverse effects.
Wang W; Wang Y
Curr Gene Ther; 2012 Dec; 12(6):493-5. PubMed ID: 22974421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
